Trademark: 86983196
Word
ALLERGAN
Status Date
Tuesday, April 10, 2018
Registration Number
5443889
Registration Date
Tuesday, April 10, 2018
Filing Date
Friday, June 12, 2015
Published for Opposition
Tuesday, March 1, 2016
5 House mark used for a line of pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations, and pharmaceutical preparations to treat and prevent glaucoma; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body; medicated cosmetic skin care preparations
10 House mark used for a line of surgical, medical, dental and veterinary apparatus and instruments, namely, diagnostic test kits principally composed of medical diagnostic meters that measure conditions of the cardio-vascular and immune systems; intra-uterine non-chemical contraceptive devices; medical diagnostic instruments for the analysis of body fluids; medical devices for treating glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for use in facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics and ophthalmic related diseases and disorders
The mark consists of the word "ALLERGAN" in a stylized dark blue font to the left of which is a stylized futuristic comet design comprised of circles that are as follows moving from right to left: three large dark blue circles, followed next by four medium blue circles that are large on the outside with the two middle circles being smaller, followed next by three small light blue circles, followed next by three large green circles, followed next by three smaller medium green circles, followed next by three small yellow circles, with the last circle being the point of the comet.
The color(s) dark blue, medium blue, light blue, green, medium green, and yellow is/are claimed as a feature of the mark.
Feb 5, 2024
Teas Section 8 & 15 Received
Apr 10, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Apr 10, 2023
Teas Change Of Correspondence Received
Apr 10, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Apr 10, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 10, 2023
Teas Change Of Owner Address Received
Apr 10, 2023
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Apr 10, 2018
Registered-Principal Register
Mar 3, 2018
Notice Of Acceptance Of Statement Of Use E-Mailed
Mar 2, 2018
Allowed Principal Register - Sou Accepted
Feb 9, 2018
Teas/Email Correspondence Entered
Feb 9, 2018
Correspondence Received In Law Office
Feb 8, 2018
Teas Request For Reconsideration Received
Oct 27, 2017
Notification Of Final Refusal Emailed
Oct 27, 2017
Final Refusal E-Mailed
Oct 27, 2017
Su - Final Refusal - Written
Oct 25, 2017
Teas/Email Correspondence Entered
Oct 25, 2017
Correspondence Received In Law Office
Oct 24, 2017
Assigned To Lie
Oct 10, 2017
Teas Response To Office Action Received
Oct 4, 2017
Notification Of Non-Final Action E-Mailed
Oct 4, 2017
Non-Final Action E-Mailed
Oct 4, 2017
Su - Non-Final Action - Written
Sep 29, 2017
Notice Of Design Search Code E-Mailed
Sep 28, 2017
Statement Of Use Processing Complete
Sep 20, 2017
Use Amendment Filed
Sep 28, 2017
Divisional Processing Complete
Sep 20, 2017
Divisional Request Received
Sep 28, 2017
Case Assigned To Intent To Use Paralegal
Sep 20, 2017
Teas Request To Divide Received
Sep 20, 2017
Teas Statement Of Use Received
Mar 28, 2017
Notice Of Approval Of Extension Request E-Mailed
Mar 24, 2017
Sou Extension 2 Granted
Mar 24, 2017
Sou Extension 2 Filed
Mar 24, 2017
Sou Teas Extension Received
Sep 16, 2016
Notice Of Approval Of Extension Request E-Mailed
Sep 14, 2016
Sou Extension 1 Granted
Sep 14, 2016
Sou Extension 1 Filed
Sep 14, 2016
Sou Teas Extension Received
Apr 26, 2016
Noa E-Mailed - Sou Required From Applicant
Mar 1, 2016
Official Gazette Publication Confirmation E-Mailed
Mar 1, 2016
Published For Opposition
Feb 10, 2016
Notification Of Notice Of Publication E-Mailed
Jan 22, 2016
Approved For Pub - Principal Register
Jan 22, 2016
Examiner's Amendment Entered
Jan 22, 2016
Notification Of Examiners Amendment E-Mailed
Jan 22, 2016
Examiners Amendment E-Mailed
Jan 22, 2016
Examiners Amendment -Written
Jan 20, 2016
Teas/Email Correspondence Entered
Jan 19, 2016
Correspondence Received In Law Office
Jan 19, 2016
Teas Response To Office Action Received
Sep 22, 2015
Notification Of Priority Action E-Mailed
Sep 22, 2015
Priority Action E-Mailed
Sep 22, 2015
Priority Action Written
Sep 22, 2015
Assigned To Examiner
Jun 18, 2015
Notice Of Design Search Code E-Mailed
Jun 17, 2015
New Application Office Supplied Data Entered
Jun 16, 2015
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
